Participating Companies


Affimed N.V. [AFMD] US$222 MM MCap
Mo­d­u­lar ROCK™plat­form en­abling mul­ti-spe­cif­ic NK / T-cell bi-and tri-spe­cif­ic Abs. Aug 2018 deal with Ge­nen­tech ($96M up­front / $5B po­ten­tial) to de­vel­op NK-cell en­gager-based ther­a­peu­tics through... [more in­for­ma­tion]
Amarin Corporation [AMRN] US$5,632 MM MCap
De­vel­op­ing/com­mer­cial­iz­ing ther­a­peu­tics to im­prove car­dio­vas­cu­lar health. Vas­ce­pa is first and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in adults. Pre­sent­ed (+) da­ta from... [more in­for­ma­tion]
Assembly Biosciences, Inc. [ASMB] US$541 MM MCap
Nov­el, oral, live bio­ther­a­peu­tics ad­dress­ing dis­eas­es as­soc w mi­cro­biome. HBV pro­gram ad­vanc­ing mul­ti­ple drug can­di­dates; ful­ly in­te­grat­ed mi­cro­biome plat­form in­cludes ro­bust strain ID and se­lec­tion... [more in­for­ma­tion]
Bellicum Pharmaceuticals Inc. [BLCM] US$147 MM MCap
Molec­u­lar switch tech­nol­o­gy and co-stim do­mains en­ables phar­ma­co­log­ic con­trol over cells for en­hanced ef­fi­ca­cy and safe­ty. Lead (reg­is­tra­tio­n­al EU) pro­gram: Ph2 for ri­vo-cel (al­pha/be­ta ad­d­back T-cell... [more in­for­ma­tion]
BerGenBio [BGBIO:OS] NKr1,466 MM MCap
De­vel­op­ing first-in-class se­lec­tive Axl ki­nase in­hibi­tors for liquid and solid can­cers, lead can­di­date is bem­cen­tinib (BG­B324) n four com­pany-spon­sored trials. Stage 2 of Ph 2 com­bi­na­tion trial with... [more in­for­ma­tion]
BioTime, Inc [BTX] US$128 MM MCap
Lead (Ph 2) cell re­place­ment can­di­date: OpRe­gen®, reti­nal pig­ment epithe­li­um tran­s­plant ther­a­py: Dry AMD. Lead cell de­liv­ery clin­i­cal pro­gram: Rene­via®: med de­vice de­vel­oped as al­ter­na­tive to... [more in­for­ma­tion]
Camurus AB [CAMX:ST] SKr2,433 MM MCap
De­vel­op­ing/com­mer­cial­iz­ing in­no­va­tive/long-act­ing medicines for se­vere & chron­ic con­di­tions (e.g. opi­oid de­pen­dence, pain, can­cer & en­docrine di­s­or­ders). Fluid­Crys­tal® drug de­liv­ery tech­nolo­gies for... [more in­for­ma­tion]
CTI BioPharma [CTIC] US$72 MM MCap
Lead can­di­date pa­cri­tinib, oral ki­nase in­hibi­tor w spe­ci­fic­i­ty for JAK2, FLT3, IRAK1, and CS­F1R in Ph 2 for treat­ment of myelo­fi­bro­sis. Up­com­ing ca­t­alysts: CHMP opinion Q1'19, com­plete en­roll­ment in... [more in­for­ma­tion]
Forbius
Pro­tein en­gi­neer­ing plat­forms /de­sign high­ly ac­tive & se­lec­tive in­hibi­tors of TGF-Be­ta and EGFR path­ways for on­co and fi­brot­ic dis­eas­es. YM Bio­s­cience spin-out (ac­quired by GILD). Ilia Tikhomirov,... [more in­for­ma­tion]
Genfit SA [GNFTF] US$637 MM MCap
Lead pro­gram Ela­fi­branor is PPAR al­pha/del­ta ag­on­ist in Ph 3 for NASH and Ph 2 for PBC. Ful­ly en­rolled in Ph 3 RE­SOLVE-IT trial for NASH w da­ta exp YE 2019. Ph 2 PBC da­ta exp YE 2018. On­go­ing NASH... [more in­for­ma­tion]
Hutchison China MediTech Ltd ("Chi-Med") [HCM] US$2,929 MM MCap
Chi-Med's pipe­line has eight nov­el late stage on­col­o­gy can­di­dates with six Phase 3 trials and 20+ Phase 1b/2 trials cur­rent­ly un­der­way that are fu­eled by its pro­f­itable Chi­nese com­mer­cial plat­form. [more in­for­ma­tion]
Kadmon Holdings, Inc. [KDMN] US$275 MM MCap
Late-stage biotech de­vel­op­ing small molecules and bi­o­log­ics; fo­cused on in­flam­ma­tion, fi­bro­sis and I-O. Lead can­di­date KD025 is a ROCK2 in­hibi­tor in a reg­is­tra­tion trial cGVHD. Plat­form of ROCK... [more in­for­ma­tion]
Medigene AG [MDG1:DB] €221 MM MCap
Lead­er in T Cell im­munol­o­gy. TCR tar­get­ing PRAME (AML, MDS, MM) en­tered clin­ic March 2018. CTA sub­mitt­ed for TCR tar­get­ing MAGE-A1 (MM, liv­er, and lung can­cer); sev­er­al add'l undis­closed tar­gets &... [more in­for­ma­tion]
Minerva Neurosciences, Inc. [NERV] US$278 MM MCap
Ph 3 trial w/rolu­peri­done tar­get­ing neg­a­tive symp­toms as­soc w/ schi­zophre­nia; du­al MOA (5-HT2A & Sig­ma2 an­ta­g­on­ist); top-line da­ta 1H19. 3 Ph 2b trials on­go­ing w/ sel­torex­ant, in­clud­ing two in MDD and... [more in­for­ma­tion]
Modus Therapeutics AB
Mo­dus Ther­a­peu­tics is a Swedish-based biotech­nol­o­gy com­pany ded­i­cat­ed to de­vel­op­ing ther­a­pies that im­prove blood flow and oxy­gen tran­s­port. The com­pany’s lead pro­ject, se­vu­parin, is cur­rent­ly in an... [more in­for­ma­tion]
MolMed [MLM:MI] €124 MM MCap
Du­al busi­ness mod­el, in­cl R&D on pro­pri­e­tary on­co and on­co-he­ma­tol­o­gy prod­ucts, and third par­ties GMP de­vt and man­u­fac­tur­ing ser­vices. Owns one of the first au­tho­rized cel­lu­lar ther­a­pies (Zal­moxis®,... [more in­for­ma­tion]
Motif Bio plc [MTFB] US$148 MM MCap
PD­U­FA date: Feb 13, 2019 for Antibi­ot­ic Iclaprim. Two Phase 3 trials in pts w acute bac­te­rial skin and skin struc­ture in­fec­tions (ABSS­SI) achieved pri­mary and se­condary end­points. Com­pared to SoC... [more in­for­ma­tion]
Oncopeptides AB [ONCO:ST] SKr5,732 MM MCap
De­vel­op­ing Melflufen (Yga­lo): alky­lat­ing pep­tide in class of Pep­ti­dase En­hanced Com­pounds tar­get­ing MM trans­for­ma­tion pro­cess, se­lec­tive­ly tar­gets MM. MoA over­comes re­sis­tance mech­anisms for cur­rent... [more in­for­ma­tion]
Oryzon Genomics [ORY:MA]
De­vel­op­ing treat­ments for the un­der­ly­ing caus­es of can­cer and CNS dis­eas­es by tar­get­ing ly­sine spe­cif­ic demethy­lase 1 (LS­D1, aka KD­M1A), an epi­ge­net­ic hi­s­tone mod­i­fy­ing en­zyme. Lead CNS com­pound... [more in­for­ma­tion]
PAION AG [PAIOF] US$164 MM MCap
Remi­ma­zo­lam: short-act­ing anes­thet­ic. Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US fil­ing exp by part­n­er Cos­mo... [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €497 MM MCap
RU­CON­EST (rhC1INH) mar­ket­ed to treat acute Hered­i­tary An­gioede­ma (HAE) at­tacks with 100% re­sponse rate, no re­lapse, side ef­fects, or plas­ma risk. Sub­mitt­ed sBLA to FDA for pro­phy­laxis of HAE (re­cent... [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] US$146 MM MCap
Plat­form tech­nol­o­gy com­pany de­vel­op­ing An­ti­calins (en­gi­neered lipo­calin pro­teins) for on­col­o­gy and re­s­pi­ra­to­ry dis­eas­es. 2H18 Phase 1 da­ta for: 1) ful­ly-pro­pri­e­tary IO pro­gram PRS-343 for HER2+ solid... [more in­for­ma­tion]
Poxel SA [POXEL:PA] €129 MM MCap
Safe/more ef­fec­tive ther­a­pies for metabolic dis­eas­es. Imeglimin (mi­to­chon­dria-based MOA) for T2D be­gan Ph 3 in Ja­pan with Asian part­n­er Su­m­i­t­o­mo Dainip­pon. Com­ple­tion of Phase 3 on track for 2019 and... [more in­for­ma­tion]
PsiOxus Therapeutics
IV ad­min­is­tered T-SIGn on­co virus plat­form trans­forms ade­n­ovirus in­to “armed” vec­tor. The ther­a­py (NG-348), us­es virus to tran­s­port two ther­a­peu­tic genes di­rect­ly in­to tu­mors to re­cruit im­mune... [more in­for­ma­tion]
ReNeuron Group plc [RENE:LN] £16 MM MCap
Clin-stage, UK-based cell ther­a­py; al­lo­gene­ic, off-the-shelf can­di­dates: chron­ic stroke dis­a­bil­i­ty (Ph3 de­sign ap­proved by FDA); re­tini­tis pig­men­tosa (Ph1/2 on­go­ing), cone rod dys­tro­phy (Ph2... [more in­for­ma­tion]
Savara Inc. [SVRA] US$259 MM MCap
Or­phan lung dis­ease co. Mol­gradex, Ph 3, in­haled GM-CSF: au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP), Ph 2a: non­tu­ber­cu­lous my­cobac­te­ria (NTM) lung in­fec­tion, and prep for Ph 2a in CF af­fect­ed... [more in­for­ma­tion]
Selvita S.A
Selvi­ta is a $225m Pol­ish on­col­o­gy fo­cused biotech­nol­o­gy com­pany. Broad on­col­o­gy tar­get­ed ther­a­peu­tics pipe­line in­cludes ki­nase in­hibi­tor and syn­thet­ic lethal­i­ty pro­grams. Lead pro­grams in­clude SEL24,... [more in­for­ma­tion]
Solebury Trout
The Trout Group is the lead­ing glob­al in­ves­tor re­la­tions and strate­g­ic ad­vi­so­ry firm ser­vic­ing the life sci­ences in­dus­try. Since 1996, the firm has been pro­vid­ing com­pa­nies with ex­pert counsel and... [more in­for­ma­tion]
STRATEC Biomedical AG [SBS:FF] €664 MM MCap
Au­to­ma­tion sys­tems and soft­ware for di­ag­nos­tics in­dus­try. In­s­talled base of >13,000 sys­tems across 20 fam­i­lies in­clud­ing PAN­THER (Ho­log­ic), Li­a­son XL (Di­a­Sorin), VI­DAS (BioMerieux) and AD­VIA... [more in­for­ma­tion]
Syneos Health [SYNH] US$5,018 MM MCap
On­ly ful­ly in­te­grat­ed bio­phar­ma­ceu­ti­cal so­lu­tions or­gani­za­tion in­cl CRO and Con­tract Com­mer­cial Or­gani­za­tion (CCO). Cre­at­ed through merg­er of INC Re­search and in­Ven­tiv Health. 23,000+ clin­i­cal & comml... [more in­for­ma­tion]
Targovax [TRVX:OS] NKr471 MM MCap
En­gi­neered on­co­lyt­ic virus armed w im­mune-sti­m­u­lat­ing trans­genes for pa­tients w solid tu­mors. Ph 1 and Ph 1/2 trials on­go­ing with mul­ti­ple da­ta read­outs in 2018 and 2019. CMO de­vel­oped Yer­voy at BMS. [more in­for­ma­tion]